On Wednesday, AbbVie Inc. (NYSE:ABBV) purchased a rare pediatric priority review voucher from United Therapeutics Corporation (NASDAQ:UTHR) for $350 million. United had received the voucher in March after the Food and Drug Administration (FDA) approved its drug, Unituxin, for the…
CVS Health Corp (NYSE:CVS) and Express Scripts Holding Co. (NASDAQ:ESRX) continue to slash off drugs from their formularies list. CVS is most aggressive in removing drugs from the formulary list. The pharmacy manager has removed as many as 31 additional…
It isn't too often that a celebrity spokesperson for Big Pharma goes off the reservation. But in the case of celebutante Kim Kardashian and Canadian pharma Duchesnay, that's exactly what happened. The FDA is coming down on the celeb's social…
Gilead Sciences, Inc. (NASDAQ:GILD) currently rules the US HCV market with around 95% market share, leaving its rival, AbbVie Inc (NYSE:ABBV), far behind in the race, according to Symphony Health Data used by Bloomberg Intelligence. Approximately 3.2 million individuals are…
Anthem Inc. struck a deal to buy rival Cigna Corp. for $48.4 billion, wrapping up almost a year of contentious negotiations and potentially creating the largest health insurer in the U.S. Anthem will pay $188 a share in cash and…
Aetna Inc. (NYSE:AET), the third-largest health insurer in the US, announced Friday it has agreed to acquire its smaller rival Humana Inc. (NYSE:HUM) for $34.1 billion, following weeks of merger-related speculation concerning the health insurance giants. The said deal is…
Cigna Corporation (NYSE:CI), one of the leading health benefits provider in the US, has once again turned down acquisition offer from Anthem Inc. (NYSE:ANTM), saying it is not in the best interests of the company’s shareholders, according to the Wall…
Amgen, Inc. (NASDAQ:AMGN) announced that its cancer drug was successful in meeting the main endpoints, improved overall survival rate in the patients who are suffering from metastatic colorectal cancer and have not responded to chemotherapy. The phase III clinical trial…
Valeant Pharmaceuticals said it will buy Salix Pharmaceuticals for $10 billion. The Quebec-based company said it would pay $158 per share for Salix. The deal will take Valeant into the multibillion dollar market for drugs treating stomach disorders like traveler's…